Results 171 to 180 of about 6,976 (185)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Journal of Clinical Oncology, 2020
Nancy U Lin, Virginia F Borges, Carey K Anders   +2 more
exaly  

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Lancet Oncology, The, 2020
Sandra M Swain, Martina Uttenreuther-Fischer, Young-Hyuck Im   +2 more
exaly  

HER2-targeted therapies — a role beyond breast cancer

Nature Reviews Clinical Oncology, 2019
Yung-Jue Bang
exaly  

Trastuzumab/trastuzumab-deruxtecan

Reactions Weekly
openaire   +1 more source

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Cancer Cell, 2004
Keng-Hsueh Lan, Ming Tan, Gabriel N Hortobagyi   +2 more
exaly  

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Nature Reviews Clinical Oncology, 2009
Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi   +2 more
exaly  

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Lancet, The, 2017
David A Cameron, Evandro de Azambuja, Ian Smith   +2 more
exaly  

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Cancer Cell, 2009
Teemu T Junttila, Gail D Lewis Phillips
exaly  

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Lancet, The, 2012
José Baselga, Serena Di Cosimo, Evandro de Azambuja   +2 more
exaly  

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Lancet Oncology, The, 2016
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino   +2 more
exaly